HEALTHglobal
Rhythm's Imcivree loses tempo across 4 rare genetic obesities, delivering phase 3 flop - Fierce Pharma
Single source
Updated 3 hours ago
First seen March 17, 2026 16:51:33Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
Rhythm's Imcivree loses tempo across 4 rare genetic obesities, delivering phase 3 flop Fierce Pharma